Search Results - "Monkhorst, Kim"

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The Probability to Initiate X Chromosome Inactivation Is Determined by the X to Autosomal Ratio and X Chromosome Specific Allelic Properties.

Authors: Monkhorst, Kim de Hoon, Bas Jonkers, Iris et al.

Source: PLoS ONE. 2009, Vol. 4 Issue 5, p1-14. 14p. 1 Chart, 4 Graphs.

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.

Authors: Schipper, Luuk J. Monkhorst, Kim Samsom, Kris G. et al.

Source: Cancers. Feb2022, Vol. 14 Issue 2, p436-436. 1p.

Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study.

Authors: Schuurbiers, Milou M. F. Smith, Christopher G. Hartemink, Koen J. et al.

Source: PLoS Medicine. 4/15/2025, Vol. 22 Issue 4, p1-23. 23p.

Challenges in breast cancer genetic testing. A call for novel forms of multidisciplinary care and long-term evaluation.

Authors: Menko, Fred H. Monkhorst, Kim Hogervorst, Frans B.L. et al.

Source: Critical Reviews in Oncology/Hematology. Aug2022, Vol. 176, pN.PAG-N.PAG. 1p.

Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.

Authors: Hummelink, Karlijn van der Noort, Vincent Muller, Mirte et al.

Source: PLoS ONE. 7/31/2024, Vol. 19 Issue 7, p1-21. 21p.

Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.

Authors: Douma, Li-Anne H van der Noort, Vincent Lalezari, Ferry et al.

Source: Lancet Oncology. Dec2025, Vol. 26 Issue 12, p1676-1684. 9p.

Generation and characterization of an inducible transgenic model for studying mouse esophageal biology.

Authors: Roth, Sabrina Franken, Patrick Monkhorst, Kim et al.

Source: BMC Developmental Biology. 2012, Vol. 12 Issue 1, p18-24. 7p. 2 Color Photographs, 1 Diagram, 1 Graph.

This result is not displayed to guests.
Login for full access.

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance.

Authors: Koole, Simone N. Vessies, Daan C. L. Schuurbiers, Milou M. F. et al.

Source: Cancers. Apr2022, Vol. 14 Issue 7, p1783. 16p.

Prevalence and Clinical Association of CD276 (B7-H3) Expression in Pleural Mesothelioma: Results From the European Thoracic Platform Mesoscape Project.

Authors: Haberecker, Martina Rüschoff, Jan H. Andriakopoulou, Charitini et al.

Source: JCO Precision Oncology. 2/12/2025, Vol. 9, p1-14. 14p.

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products.

Authors: Castenmiller, Suzanne M. Kanagasabesan, Nandhini Guislain, Aurélie et al.

Source: OncoImmunology. 2024, Vol. 13 Issue 1, p1-16. 16p.

Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer.

Authors: Radonic, Teodora Rahmani-Khajouei, Sepehr Dafni, Urania et al.

Source: Lung Cancer (01695002). Aug2026, Vol. 218, pN.PAG-N.PAG. 1p.

Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary.

Authors: Martinot, Tobias Schonewille, Lydia H.N. Ruano, Dina et al.

Source: Lung Cancer (01695002). Aug2026, Vol. 218, pN.PAG-N.PAG. 1p.

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer.

Authors: van Veggel, Bianca A. M. H. van der Wekken, Anthonie J. Paats, Marthe S. et al.

Source: Cancer (0008543X). Mar2024, Vol. 130 Issue 5, p683-691. 9p.

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

Authors: Theelen, Willemijn S. M. E. Kuilman, Thomas Schulze, Katja et al.

Source: PLoS ONE. 5/24/2019, Vol. 14 Issue 5, p1-13. 13p.

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.

Authors: Douma, Li-Anne H Lalezari, Ferry van der Noort, Vincent et al.

Source: Lancet Oncology. Nov2023, Vol. 24 Issue 11, p1219-1228. 10p.

The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer.

Authors: Butter, Rogier Hondelink, Liesbeth M. van Elswijk, Lisette et al.

Source: Lung Cancer (01695002). Apr2022, Vol. 166, p143-149. 7p.